{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T18:17:39Z","timestamp":1791137859520,"version":"4.1.0"},"reference-count":94,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2014,3,1]],"date-time":"2014-03-01T00:00:00Z","timestamp":1393632000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Drug Discovery Today: Technologies"],"published-print":{"date-parts":[[2014,3]]},"DOI":"10.1016\/j.ddtec.2014.03.003","type":"journal-article","created":{"date-parts":[[2014,3,26]],"date-time":"2014-03-26T12:48:59Z","timestamp":1395838139000},"page":"89-99","source":"Crossref","is-referenced-by-count":70,"special_numbering":"C","title":["Current aspects in resistance against tyrosine kinase inhibitors in chronic myelogenous leukemia"],"prefix":"10.1016","volume":"11","author":[{"given":"Stefan","family":"Balabanov","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melanie","family":"Braig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tim H.","family":"Br\u00fcmmendorf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ddtec.2014.03.003_bib0005","first-page":"151","article-title":"Weisses Blut","volume":"36","author":"Virchow","year":"1845","journal-title":"Frorieps Notizen"},{"key":"10.1016\/j.ddtec.2014.03.003_bib0010","first-page":"413","article-title":"Case of hypertrophy of the spleen and liver in which death took place from the suppuration of the blood","volume":"64","author":"Bennett","year":"1845","journal-title":"Edinburgh Med Surg J"},{"key":"10.1016\/j.ddtec.2014.03.003_bib0015","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1053\/j.seminhematol.2010.07.001","article-title":"Chronic myeloid leukemia: a historical perspective","volume":"47","author":"Goldman","year":"2010","journal-title":"Semin Hematol"},{"key":"10.1016\/j.ddtec.2014.03.003_bib0020","article-title":"A minute chromosome in human chronic granulocytic leukemia","volume":"132","author":"Nowell","year":"1960","journal-title":"Science"},{"key":"10.1016\/j.ddtec.2014.03.003_bib0025","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/243290a0","article-title":"Letter: a new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining","volume":"243","author":"Rowley","year":"1973","journal-title":"Nature"},{"key":"10.1016\/j.ddtec.2014.03.003_bib0030","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1038\/306277a0","article-title":"Translocation of c-ab1 oncogene correlates with the presence of a Philadelphia chromosome in chronic myelocytic leukaemia","volume":"306","author":"Bartram","year":"1983","journal-title":"Nature"},{"key":"10.1016\/j.ddtec.2014.03.003_bib0035","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/0092-8674(84)90077-1","article-title":"Philadelphia chromosomal breakpoints are clustered within a limited region, bcr, on chromosome 22","volume":"36","author":"Groffen","year":"1984","journal-title":"Cell"},{"key":"10.1016\/j.ddtec.2014.03.003_bib0040","series-title":"ASH Education Program Book 2001","first-page":"87","article-title":"Chronic myelogenous leukemia","author":"Druker","year":"2001"},{"key":"10.1016\/j.ddtec.2014.03.003_bib0045","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1126\/science.2406902","article-title":"Induction of chronic myelogenous leukemia in mice by the P210bcr\/abl gene of the Philadelphia chromosome","volume":"247","author":"Daley","year":"1990","journal-title":"Science"},{"key":"10.1016\/j.ddtec.2014.03.003_bib0050","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/nm0596-561","article-title":"Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells","volume":"2","author":"Druker","year":"1996","journal-title":"Nat Med"},{"key":"10.1016\/j.ddtec.2014.03.003_bib0055","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1056\/NEJM200104053441401","article-title":"Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia","volume":"344","author":"Druker","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ddtec.2014.03.003_bib0060","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1056\/NEJMoa022457","article-title":"Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia","volume":"348","author":"O\u2019Brien","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ddtec.2014.03.003_bib0065","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1056\/NEJMoa062867","article-title":"Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia","volume":"355","author":"Druker","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ddtec.2014.03.003_bib0070","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1038\/leu.2009.38","article-title":"Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia","volume":"23","author":"Hochhaus","year":"2009","journal-title":"Leukemia"},{"key":"10.1016\/j.ddtec.2014.03.003_bib0075","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1016\/S1470-2045(07)70342-X","article-title":"Part I: mechanisms of resistance to imatinib in chronic myeloid leukaemia","volume":"8","author":"Apperley","year":"2007","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ddtec.2014.03.003_bib0080","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.ccr.2005.01.007","article-title":"Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl","volume":"7","author":"Weisberg","year":"2005","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ddtec.2014.03.003_bib0085","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa055229","article-title":"Dasatinib in imatinib-resistant Philadelphia chromosome positive leukemias","volume":"354","author":"Talpaz","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ddtec.2014.03.003_bib0090","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1126\/science.1099480","article-title":"Overriding imatinib resistance with a novel ABL kinase inhibitor","volume":"305","author":"Shah","year":"2004","journal-title":"Science"},{"key":"10.1016\/j.ddtec.2014.03.003_bib0095","doi-asserted-by":"crossref","first-page":"3486","DOI":"10.1200\/JCO.2011.38.7522","article-title":"Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: results from the BELA trial","volume":"30","author":"Cortes","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ddtec.2014.03.003_bib0100","article-title":"Bosutinib safety and management of toxicity in leukemia patients with resistance or intolerance to imatinib and other tyrosine kinase inhibitors","author":"Kantarjian","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.ddtec.2014.03.003_bib0105","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.ccr.2009.09.028","article-title":"AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance","volume":"16","author":"O\u2019Hare","year":"2009","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ddtec.2014.03.003_bib0110","doi-asserted-by":"crossref","first-page":"4005","DOI":"10.1182\/blood-2007-03-080838","article-title":"Dynamics of BCR-ABL kinase domain mutations in chronic myeloid leukemia after sequential treatment with multiple tyrosine kinase inhibitors","volume":"110","author":"Cortes","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.ddtec.2014.03.003_bib0115","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1038\/nrm1280","article-title":"Regulation of the c-Abl and Bcr-Abl tyrosine kinases","volume":"5","author":"Hantschel","year":"2004","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"5\u20136","key":"10.1016\/j.ddtec.2014.03.003_bib0120","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1177\/1947601912462126","article-title":"The ins and outs of bcr-abl inhibition","volume":"3","author":"Reddy","year":"2012","journal-title":"Genes Cancer"},{"issue":"2","key":"10.1016\/j.ddtec.2014.03.003_bib0125","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/S0960-894X(96)00601-4","article-title":"Potent and selective inhibitors of the Abl-kinase: phenylaminopyrimidine (PAP) derivatives","volume":"7","author":"Zimmermann","year":"1997","journal-title":"Bioorg Med Chem Lett"},{"issue":"5486","key":"10.1016\/j.ddtec.2014.03.003_bib0130","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1126\/science.289.5486.1938","article-title":"Structural mechanism for STI-571 inhibition of Abelson tyrosine kinase","volume":"289","author":"Schindler","year":"2000","journal-title":"Science"},{"issue":"26","key":"10.1016\/j.ddtec.2014.03.003_bib0135","doi-asserted-by":"crossref","first-page":"18292","DOI":"10.1074\/jbc.M801337200","article-title":"Solution conformations and dynamics of ABL kinase-inhibitor complexes determined by nmr substantiate the different binding modes of imatinib\/nilotinib and dasatinib","volume":"283","author":"Vajpai","year":"2008","journal-title":"J Biol Chem"},{"issue":"2","key":"10.1016\/j.ddtec.2014.03.003_bib0140","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.ceb.2009.01.014","article-title":"The interplay of structural information and functional studies in kinase drug design: insights from BCR-Abl","volume":"21","author":"Eck","year":"2009","journal-title":"Curr Opin Cell Biol"},{"issue":"47","key":"10.1016\/j.ddtec.2014.03.003_bib0145","doi-asserted-by":"crossref","first-page":"E4437","DOI":"10.1073\/pnas.1314712110","article-title":"NMR reveals the allosteric opening and closing of Abelson tyrosine kinase by ATP-site and myristoyl pocket inhibitors","volume":"110","author":"Skora","year":"2013","journal-title":"Proc Natl Acad Sci"},{"issue":"23","key":"10.1016\/j.ddtec.2014.03.003_bib0150","doi-asserted-by":"crossref","first-page":"5793","DOI":"10.1016\/j.bmcl.2004.09.042","article-title":"Urea derivatives of STI571 as inhibitors of Bcr-Abl and PDGFR kinases","volume":"14","author":"Manley","year":"2004","journal-title":"Bioorg Med Chem Lett"},{"issue":"19","key":"10.1016\/j.ddtec.2014.03.003_bib0155","doi-asserted-by":"crossref","first-page":"6977","DOI":"10.1016\/j.bmc.2010.08.026","article-title":"Structural resemblances and comparisons of the relative pharmacological properties of imatinib and nilotinib","volume":"18","author":"Manley","year":"2010","journal-title":"Bioorg Med Chem"},{"issue":"11","key":"10.1016\/j.ddtec.2014.03.003_bib0160","doi-asserted-by":"crossref","first-page":"5790","DOI":"10.1158\/0008-5472.CAN-05-4187","article-title":"The structure of dasatinib (BMS-354825) bound to activated ABL kinase domain elucidates its inhibitory activity against imatinib-resistant ABL mutants","volume":"66","author":"Tokarski","year":"2006","journal-title":"Cancer Res"},{"issue":"4","key":"10.1016\/j.ddtec.2014.03.003_bib0165","doi-asserted-by":"crossref","first-page":"e29828","DOI":"10.1371\/journal.pone.0029828","article-title":"Structural and spectroscopic analysis of the kinase inhibitor bosutinib and an isomer of bosutinib binding to the Abl tyrosine kinase domain","volume":"7","author":"Levinson","year":"2012","journal-title":"PLoS ONE"},{"key":"10.1016\/j.ddtec.2014.03.003_bib0170","doi-asserted-by":"crossref","DOI":"10.1038\/nchembio.1404","article-title":"A conserved water-mediated hydrogen bond network defines bosutinib's kinase selectivity","author":"Levinson","year":"2013","journal-title":"Nat Chem Biol"},{"issue":"22","key":"10.1016\/j.ddtec.2014.03.003_bib0175","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1056\/NEJMoa1205127","article-title":"Ponatinib in refractory Philadelphia chromosome-positive leukemias","volume":"367","author":"Cortes","year":"2012","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.ddtec.2014.03.003_bib0180","doi-asserted-by":"crossref","first-page":"4701","DOI":"10.1021\/jm100395q","volume":"53","author":"Huang","year":"2010","journal-title":"J Med Chem"},{"issue":"11","key":"10.1016\/j.ddtec.2014.03.003_bib0185","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1038\/nbt.2017","article-title":"Comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity","volume":"29","author":"Anastassiadis","year":"2011","journal-title":"Nat Biotech"},{"issue":"11","key":"10.1016\/j.ddtec.2014.03.003_bib0190","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1038\/nbt.1990","article-title":"Comprehensive analysis of kinase inhibitor selectivity","volume":"29","author":"Davis","year":"2011","journal-title":"Nat Biotech"},{"issue":"12","key":"10.1016\/j.ddtec.2014.03.003_bib0195","doi-asserted-by":"crossref","first-page":"4055","DOI":"10.1182\/blood-2007-07-102061","article-title":"Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets","volume":"110","author":"Rix","year":"2007","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.ddtec.2014.03.003_bib0200","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1038\/nbt1328","article-title":"Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitors","volume":"25","author":"Bantscheff","year":"2007","journal-title":"Nat Biotech"},{"issue":"8","key":"10.1016\/j.ddtec.2014.03.003_bib0205","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1200\/JCO.2011.37.1195","article-title":"Meta-analysis of randomized controlled trials for the incidence and risk of treatment-related mortality in patients with cancer treated with vascular endothelial growth factor tyrosine kinase inhibitors","volume":"30","author":"Schutz","year":"2012","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.ddtec.2014.03.003_bib0210","doi-asserted-by":"crossref","first-page":"e53668","DOI":"10.1371\/journal.pone.0053668","article-title":"Combination of a proteomics approach and reengineering of meso scale network models for prediction of mode-of-action for tyrosine kinase inhibitors","volume":"8","author":"Balabanov","year":"2013","journal-title":"PLoS ONE"},{"issue":"21","key":"10.1016\/j.ddtec.2014.03.003_bib0215","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1182\/blood.V122.21.257.257","article-title":"Nilotinib exerts direct pro-atherogenic and anti-angiogenic effects on vascular endothelial cells: a potential explanation for drug-induced vasculopathy in CML","volume":"122","author":"Emir","year":"2013","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.ddtec.2014.03.003_bib0220","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1182\/blood-2013-05-501569","article-title":"European LeukemiaNet recommendations for the management of chronic myeloid leukemia","volume":"122","author":"Baccarani","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.ddtec.2014.03.003_bib0225","article-title":"Early molecular response predicts outcomes in patients with chronic myeloid leukemia in chronic phase treated with frontline nilotinib or imatinib","author":"Hughes","year":"2013","journal-title":"Blood"},{"issue":"5531","key":"10.1016\/j.ddtec.2014.03.003_bib0230","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1126\/science.1062538","article-title":"Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification","volume":"293","author":"Gorre","year":"2001","journal-title":"Science"},{"issue":"10","key":"10.1016\/j.ddtec.2014.03.003_bib0235","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1038\/sj.leu.2404318","article-title":"Frequency and clinical significance of BCR-ABL mutations in patients with chronic myeloid leukemia treated with imatinib mesylate","volume":"20","author":"Jabbour","year":"2006","journal-title":"Leukemia"},{"issue":"Suppl 1","key":"10.1016\/j.ddtec.2014.03.003_bib0240","doi-asserted-by":"crossref","first-page":"12","DOI":"10.3109\/10428194.2010.546920","article-title":"Mechanisms of resistance to BCR-ABL kinase inhibitors","volume":"52","author":"Diamond","year":"2011","journal-title":"Leuk Lymphoma"},{"issue":"6","key":"10.1016\/j.ddtec.2014.03.003_bib0245","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/S0092-8674(03)00190-9","article-title":"Mechanisms of autoinhibition and STI-571\/imatinib resistance revealed by mutagenesis of BCR-ABL","volume":"112","author":"Azam","year":"2003","journal-title":"Cell"},{"issue":"17","key":"10.1016\/j.ddtec.2014.03.003_bib0250","doi-asserted-by":"crossref","first-page":"3278","DOI":"10.1182\/blood-2008-10-183665","article-title":"BCR-ABL SH3-SH2 domain mutations in chronic myeloid leukemia patients on imatinib","volume":"116","author":"Sherbenou","year":"2010","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.ddtec.2014.03.003_bib0255","doi-asserted-by":"crossref","first-page":"2562","DOI":"10.1172\/JCI30890","article-title":"Sequential ABL kinase inhibitor therapy selects for compound drug-resistant BCR-ABL mutations with altered oncogenic potency","volume":"117","author":"Shah","year":"2007","journal-title":"J Clin Invest"},{"issue":"3","key":"10.1016\/j.ddtec.2014.03.003_bib0260","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1182\/blood-2012-05-431379","article-title":"BCR-ABL1 compound mutations in tyrosine kinase inhibitor-resistant CML: frequency and clonal relationships","volume":"121","author":"Khorashad","year":"2013","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.ddtec.2014.03.003_bib0265","doi-asserted-by":"crossref","first-page":"2168","DOI":"10.1182\/blood-2009-01-197186","article-title":"Philadelphia-positive patients who already harbor imatinib-resistant Bcr-Abl kinase domain mutations have a higher likelihood of developing additional mutations associated with resistance to second- or third-line tyrosine kinase inhibitors","volume":"114","author":"Soverini","year":"2009","journal-title":"Blood"},{"issue":"25","key":"10.1016\/j.ddtec.2014.03.003_bib0270","doi-asserted-by":"crossref","first-page":"4204","DOI":"10.1200\/JCO.2009.21.8230","article-title":"Impact of baseline BCR-ABL mutations on response to nilotinib in patients with chronic myeloid leukemia in chronic phase","volume":"27","author":"Hughes","year":"2009","journal-title":"J Clin Oncol"},{"issue":"23","key":"10.1016\/j.ddtec.2014.03.003_bib0275","doi-asserted-by":"crossref","first-page":"9809","DOI":"10.1158\/0008-5472.CAN-08-1008","article-title":"Evidence that resistance to nilotinib may be due to BCR-ABL, Pgp, or Src kinase overexpression","volume":"68","author":"Mahon","year":"2008","journal-title":"Cancer Res"},{"issue":"5","key":"10.1016\/j.ddtec.2014.03.003_bib0280","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.1182\/blood.V95.5.1758.005a41_1758_1766","article-title":"Induction of resistance to the Abelson inhibitor STI571 in human leukemic cells through gene amplification","volume":"95","author":"le Coutre","year":"2000","journal-title":"Blood"},{"issue":"19","key":"10.1016\/j.ddtec.2014.03.003_bib0285","doi-asserted-by":"crossref","first-page":"8912","DOI":"10.1158\/0008-5472.CAN-05-0076","article-title":"Bcr-Abl expression levels determine the rate of development of resistance to imatinib mesylate in chronic myeloid leukemia","volume":"65","author":"Barnes","year":"2005","journal-title":"Cancer Res"},{"issue":"6","key":"10.1016\/j.ddtec.2014.03.003_bib0290","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1182\/blood-2010-12-326843","article-title":"Chronic myeloid leukemia stem cells are not dependent on Bcr-Abl kinase activity for their survival","volume":"119","author":"Hamilton","year":"2012","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.ddtec.2014.03.003_bib0295","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1172\/JCI35721","article-title":"Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity","volume":"121","author":"Corbin","year":"2011","journal-title":"J Clin Investig"},{"issue":"8","key":"10.1016\/j.ddtec.2014.03.003_bib0300","doi-asserted-by":"crossref","first-page":"3496","DOI":"10.1182\/blood-2006-07-036012","article-title":"Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia","volume":"109","author":"Picard","year":"2007","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.ddtec.2014.03.003_bib0305","doi-asserted-by":"crossref","first-page":"879","DOI":"10.2165\/00003088-200544090-00001","article-title":"Clinical pharmacokinetics of imatinib","volume":"44","author":"Peng","year":"2005","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.ddtec.2014.03.003_bib0310","unstructured":"Iurlo, A. et al. Comorbidities and polypharmacy impact on complete cytogenetic response in chronic myeloid leukaemia elderly patients. Eur J Intern Med"},{"issue":"8","key":"10.1016\/j.ddtec.2014.03.003_bib0315","doi-asserted-by":"crossref","first-page":"e75","DOI":"10.1182\/blood-2010-07-294330","article-title":"Drug interactions with the tyrosine kinase inhibitors imatinib, dasatinib, and nilotinib","volume":"117","author":"Haouala","year":"2011","journal-title":"Blood"},{"issue":"14","key":"10.1016\/j.ddtec.2014.03.003_bib0320","doi-asserted-by":"crossref","first-page":"3733","DOI":"10.1182\/blood-2010-10-309807","article-title":"Poor adherence is the main reason for loss of CCyR and imatinib failure for chronic myeloid leukemia patients on long-term therapy","volume":"117","author":"Ibrahim","year":"2011","journal-title":"Blood"},{"issue":"14","key":"10.1016\/j.ddtec.2014.03.003_bib0325","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1200\/JCO.2009.26.3087","article-title":"Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib","volume":"28","author":"Marin","year":"2010","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.ddtec.2014.03.003_bib0330","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1158\/1078-0432.CCR-10-2250","article-title":"Drug transporters and imatinib treatment: implications for clinical practice","volume":"17","author":"Eechoute","year":"2011","journal-title":"Clin Cancer Res"},{"issue":"4","key":"10.1016\/j.ddtec.2014.03.003_bib0335","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1182\/blood-2006-02-003145","article-title":"Functional ABCG2 is overexpressed on primary CML CD34+ cells and is inhibited by imatinib mesylate","volume":"108","author":"Jordanides","year":"2006","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.ddtec.2014.03.003_bib0340","doi-asserted-by":"crossref","first-page":"e19164","DOI":"10.1371\/journal.pone.0019164","article-title":"Abcg2 overexpression represents a novel mechanism for acquired resistance to the multi-kinase inhibitor Danusertib in BCR-ABL-positive cells in vitro","volume":"6","author":"Balabanov","year":"2011","journal-title":"PLoS ONE"},{"key":"10.1016\/j.ddtec.2014.03.003_bib0345","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1007\/978-3-642-01222-8_14","article-title":"Danusertib (formerly PHA-739358) \u2013 a novel combined pan-Aurora kinases and third generation Bcr-Abl tyrosine kinase inhibitor","volume":"184","author":"Gontarewicz","year":"2010","journal-title":"Recent Results Cancer Res"},{"issue":"6","key":"10.1016\/j.ddtec.2014.03.003_bib0350","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1182\/blood-2005-03-1036","article-title":"High-sensitivity detection of BCR-ABL kinase domain mutations in imatinib-naive patients: correlation with clonal cytogenetic evolution but not response to therapy","volume":"106","author":"Willis","year":"2005","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.ddtec.2014.03.003_bib0355","doi-asserted-by":"crossref","first-page":"193","DOI":"10.3324\/haematol.2012.066480","article-title":"Association between imatinib transporters and metabolizing enzymes genotype and response in newly diagnosed chronic myeloid leukemia patients receiving imatinib therapy","volume":"98","author":"Angelini","year":"2013","journal-title":"Haematologica"},{"issue":"6","key":"10.1016\/j.ddtec.2014.03.003_bib0360","doi-asserted-by":"crossref","first-page":"907","DOI":"10.3324\/haematol.2011.056457","article-title":"Chronic phase chronic myeloid leukemia patients with low OCT-1 activity randomized to high-dose imatinib achieve better responses and have lower failure rates than those randomized to standard-dose imatinib","volume":"97","author":"White","year":"2012","journal-title":"Haematologica"},{"issue":"12","key":"10.1016\/j.ddtec.2014.03.003_bib0365","doi-asserted-by":"crossref","first-page":"3881","DOI":"10.1158\/1078-0432.CCR-07-5095","article-title":"Dasatinib cellular uptake and efflux in chronic myeloid leukemia cells: therapeutic implications","volume":"14","author":"Hiwase","year":"2008","journal-title":"Clin Cancer Res"},{"issue":"10","key":"10.1016\/j.ddtec.2014.03.003_bib0370","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1038\/sj.leu.2403898","article-title":"Compensatory PI3-kinase\/Akt\/mTor activation regulates imatinib resistance development","volume":"19","author":"Burchert","year":"2005","journal-title":"Leukemia"},{"issue":"28","key":"10.1016\/j.ddtec.2014.03.003_bib0375","doi-asserted-by":"crossref","first-page":"21446","DOI":"10.1074\/jbc.M109.090043","article-title":"Expression of a Src family kinase in chronic myelogenous leukemia cells induces resistance to imatinib in a kinase-dependent manner","volume":"285","author":"Pene-Dumitrescu","year":"2010","journal-title":"J Biol Chem"},{"issue":"13","key":"10.1016\/j.ddtec.2014.03.003_bib0380","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1093\/jnci\/djn188","article-title":"Association between imatinib-resistant BCR-ABL mutation-negative leukemia and persistent activation of LYN kinase","volume":"100","author":"Wu","year":"2008","journal-title":"J Natl Cancer Inst"},{"issue":"4260","key":"10.1016\/j.ddtec.2014.03.003_bib0385","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1126\/science.959840","article-title":"The clonal evolution of tumor cell populations","volume":"194","author":"Nowell","year":"1976","journal-title":"Science"},{"issue":"9","key":"10.1016\/j.ddtec.2014.03.003_bib0390","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1182\/blood-2013-03-487728","article-title":"Unraveling the complexity of tyrosine kinase inhibitor\u2013resistant populations by ultra-deep sequencing of the BCR-ABL kinase domain","volume":"122","author":"Soverini","year":"2013","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.ddtec.2014.03.003_bib0395","doi-asserted-by":"crossref","first-page":"e28955","DOI":"10.1371\/journal.pone.0028955","article-title":"Dynamics of resistance development to imatinib under increasing selection pressure: a combination of mathematical models and in vitro data","volume":"6","author":"Werner","year":"2011","journal-title":"PLoS ONE"},{"issue":"3","key":"10.1016\/j.ddtec.2014.03.003_bib0400","doi-asserted-by":"crossref","first-page":"360","DOI":"10.3324\/haematol.2010.030999","article-title":"Dynamics of mutant BCR-ABL-positive clones after cessation of tyrosine kinase inhibitor therapy","volume":"96","author":"Hanfstein","year":"2011","journal-title":"Haematologica"},{"issue":"3","key":"10.1016\/j.ddtec.2014.03.003_bib0405","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.jtbi.2005.08.003","article-title":"Stochastic modeling of drug resistance in cancer","volume":"239","author":"Komarova","year":"2006","journal-title":"J Theor Biol"},{"issue":"2","key":"10.1016\/j.ddtec.2014.03.003_bib0410","doi-asserted-by":"crossref","first-page":"e55717","DOI":"10.1371\/journal.pone.0055717","article-title":"Sensitive detection of pre-existing BCR-ABL kinase domain mutations in CD34+ cells of newly diagnosed chronic-phase chronic myeloid leukemia patients is associated with imatinib resistance: implications in the post-imatinib era","volume":"8","author":"Iqbal","year":"2013","journal-title":"PLoS ONE"},{"issue":"12","key":"10.1016\/j.ddtec.2014.03.003_bib0415","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1200\/JCO.2010.32.0598","article-title":"Tolerability-adapted imatinib 800 mg\/d versus 400 mg\/d versus 400 mg\/d plus interferon-\u03b1 in newly diagnosed chronic myeloid leukemia","volume":"29","author":"Hehlmann","year":"2011","journal-title":"J Clin Oncol"},{"issue":"19","key":"10.1016\/j.ddtec.2014.03.003_bib0420","doi-asserted-by":"crossref","first-page":"4497","DOI":"10.1182\/blood-2008-12-191254","article-title":"Comparison of imatinib 400 mg and 800 mg daily in the front-line treatment of high-risk, Philadelphia-positive chronic myeloid leukemia: a European LeukemiaNet Study","volume":"113","author":"Baccarani","year":"2009","journal-title":"Blood"},{"issue":"24","key":"10.1016\/j.ddtec.2014.03.003_bib0425","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1056\/NEJMoa055104","article-title":"Nilotinib in imatinib-resistant CML and Philadelphia Chromosome Positive ALL","volume":"354","author":"Kantarjian","year":"2006","journal-title":"N Engl J Med"},{"issue":"15","key":"10.1016\/j.ddtec.2014.03.003_bib0430","doi-asserted-by":"crossref","first-page":"3403","DOI":"10.1182\/blood-2011-11-390120","article-title":"Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and\/or nilotinib therapy failure","volume":"119","author":"Khoury","year":"2012","journal-title":"Blood"},{"issue":"24","key":"10.1016\/j.ddtec.2014.03.003_bib0435","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1056\/NEJMoa0912614","article-title":"Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia","volume":"362","author":"Saglio","year":"2010","journal-title":"N Engl J Med"},{"issue":"24","key":"10.1016\/j.ddtec.2014.03.003_bib0440","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1056\/NEJMoa1002315","article-title":"Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia","volume":"362","author":"Kantarjian","year":"2010","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.ddtec.2014.03.003_bib0445","first-page":"1450","article-title":"Bafetinib, a dual Bcr-Abl\/Lyn tyrosine kinase inhibitor for the potential treatment of leukemia","volume":"11","author":"Santos","year":"2010","journal-title":"Curr Opin Investig Drugs"},{"issue":"9","key":"10.1016\/j.ddtec.2014.03.003_bib0450","doi-asserted-by":"crossref","first-page":"3189","DOI":"10.1158\/0008-5472.CAN-10-3224","article-title":"The ABL switch control inhibitor DCC-2036 is active against the chronic myeloid leukemia mutant BCR-ABLT315I and exhibits a narrow resistance profile","volume":"71","author":"Eide","year":"2011","journal-title":"Cancer Res"},{"issue":"18","key":"10.1016\/j.ddtec.2014.03.003_bib0455","doi-asserted-by":"crossref","first-page":"3710","DOI":"10.4161\/cc.9.18.13232","article-title":"Allosteric inhibition of BCR-ABL","volume":"9","author":"Hassan","year":"2010","journal-title":"Cell Cycle"},{"issue":"1","key":"10.1016\/j.ddtec.2014.03.003_bib0460","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/1756-8722-7-2","article-title":"Homoharringtonine and omacetaxine for myeloid hematological malignancies","volume":"7","author":"Lu","year":"2014","journal-title":"J Hematol Oncol"},{"issue":"7","key":"10.1016\/j.ddtec.2014.03.003_bib0465","doi-asserted-by":"crossref","first-page":"2242","DOI":"10.1182\/blood-2007-03-066936","article-title":"Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia","volume":"110","author":"O\u2019Hare","year":"2007","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.ddtec.2014.03.003_bib0470","doi-asserted-by":"crossref","first-page":"E125","DOI":"10.1002\/ajh.23338","article-title":"Three novel patient-derived BCR\/ABL mutants show different sensitivity to second and third generation tyrosine kinase inhibitors","volume":"87","author":"Redaelli","year":"2012","journal-title":"Am J Hematol"}],"container-title":["Drug Discovery Today: Technologies"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1740674914000092?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1740674914000092?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,8,16]],"date-time":"2020-08-16T21:07:12Z","timestamp":1597612032000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1740674914000092"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,3]]},"references-count":94,"alternative-id":["S1740674914000092"],"URL":"https:\/\/doi.org\/10.1016\/j.ddtec.2014.03.003","relation":{},"ISSN":["1740-6749"],"issn-type":[{"value":"1740-6749","type":"print"}],"subject":[],"published":{"date-parts":[[2014,3]]}}}